Ignite Creation Date:
2025-12-26 @ 10:18 PM
Ignite Modification Date:
2025-12-26 @ 10:18 PM
Study NCT ID:
NCT04915612
Status:
COMPLETED
Last Update Posted:
2025-04-27
First Post:
2021-02-25
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia
Sponsor:
M.D. Anderson Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-05-21
Start Date Type:
ACTUAL
Primary Completion Date:
2025-01-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-01-30
Completion Date Type:
ACTUAL
First Submit Date:
2021-02-25
First Submit QC Date:
None
Study First Post Date:
2021-06-07
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-23
Last Update Post Date:
2025-04-27
Last Update Post Date Type:
ACTUAL